About: Conbercept

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs.

Property Value
dbo:abstract
  • Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs. Conbercept was developed by Chengdu Kanghong Biotech Company in the People’s Republic of China and is marketed under the name Lumitin. (en)
dbo:alternativeName
  • Lumitin (en)
dbo:casNumber
  • 1227158-72-6
dbo:fdaUniiCode
  • 1P05PW62F3
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 66240342 (xsd:integer)
dbo:wikiPageLength
  • 16299 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1105246899 (xsd:integer)
dbo:wikiPageWikiLink
dbp:casNumber
  • 1227158 (xsd:integer)
dbp:molecularWeight
  • 142 (xsd:integer)
dbp:routesOfAdministration
  • Intravitreal Injection (en)
dbp:tradename
  • Lumitin (en)
dbp:unii
  • 1 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs. (en)
rdfs:label
  • Conbercept (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License